BR112012001395A2 - metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero - Google Patents

metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero

Info

Publication number
BR112012001395A2
BR112012001395A2 BR112012001395A BR112012001395A BR112012001395A2 BR 112012001395 A2 BR112012001395 A2 BR 112012001395A2 BR 112012001395 A BR112012001395 A BR 112012001395A BR 112012001395 A BR112012001395 A BR 112012001395A BR 112012001395 A2 BR112012001395 A2 BR 112012001395A2
Authority
BR
Brazil
Prior art keywords
her2
mammal
positive cancer
positive
herds
Prior art date
Application number
BR112012001395A
Other languages
English (en)
Inventor
Sapra Puja
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of BR112012001395A2 publication Critical patent/BR112012001395A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
BR112012001395A 2009-07-22 2010-07-21 metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero BR112012001395A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22759909P 2009-07-22 2009-07-22
PCT/US2010/042686 WO2011011474A1 (en) 2009-07-22 2010-07-21 Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin

Publications (1)

Publication Number Publication Date
BR112012001395A2 true BR112012001395A2 (pt) 2019-09-24

Family

ID=43499390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001395A BR112012001395A2 (pt) 2009-07-22 2010-07-21 metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero

Country Status (9)

Country Link
US (1) US20120171201A1 (pt)
EP (1) EP2456464A4 (pt)
JP (1) JP2013500253A (pt)
KR (1) KR20120104158A (pt)
CN (1) CN102481364A (pt)
AU (1) AU2010276261A1 (pt)
BR (1) BR112012001395A2 (pt)
CA (1) CA2768494A1 (pt)
WO (1) WO2011011474A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CA2835489C (en) 2010-05-10 2018-03-06 Chi-Huey Wong Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
WO2015035337A1 (en) 2013-09-06 2015-03-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
JP5721806B2 (ja) 2013-10-04 2015-05-20 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 副作用のない抗癌剤
KR102088169B1 (ko) 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
CN110464847B (zh) * 2014-01-31 2024-02-09 第一三共株式会社 抗her2抗体－药物偶联物
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
EP3130608B1 (en) * 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
TWI717319B (zh) 2014-05-27 2021-02-01 中央研究院 得自類桿菌屬之岩藻糖苷酶及其用途
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3789766A1 (en) 2015-01-24 2021-03-10 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3967705A1 (en) * 2015-02-04 2022-03-16 United Arab Emirates University Rvg derived peptides
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
TWI780104B (zh) 2017-01-17 2022-10-11 日商第一三共股份有限公司 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
EP3677568A4 (en) 2017-08-31 2021-05-12 Daiichi Sankyo Company, Limited INNOVATIVE PROCESS FOR THE PRODUCTION OF AN ANTIBODY-ACTIVE CONJUGATE
WO2019044947A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
HRP20230787T1 (hr) 2018-05-18 2023-10-27 Glycotope Gmbh Anti-muc1 antitijelo
EA202190799A1 (ru) 2018-09-17 2021-06-22 Дзе Чилдрен'З Хоспитал Оф Филадельфия Макромолекулярные пролекарства на полимерной основе

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
LT1675622T (lt) * 2003-09-17 2017-09-11 Nektar Therapeutics Daugiašakio polimero provaistai
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
RU2009133793A (ru) * 2007-02-09 2011-03-20 Энзон Фармасьютикалз, Инк. (Us) Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи
EP2173373B1 (en) * 2007-06-06 2020-04-15 Sarepta Therapeutics, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease

Also Published As

Publication number Publication date
EP2456464A4 (en) 2013-02-20
EP2456464A1 (en) 2012-05-30
KR20120104158A (ko) 2012-09-20
US20120171201A1 (en) 2012-07-05
CN102481364A (zh) 2012-05-30
AU2010276261A1 (en) 2012-02-02
WO2011011474A1 (en) 2011-01-27
JP2013500253A (ja) 2013-01-07
CA2768494A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
BR112012001395A2 (pt) metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
DK2766040T3 (da) Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
BR112013008816A2 (pt) método de tratamento de câncer direcionado ao egfr resistente à erlotinibe ou gefitinibe, ou uso de um sal farmacêuticamente aceito em um indivíduo
BR112013027734A2 (pt) compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
EP2696792A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF THE MAGIC / FOOD TUBE REFLUX DISEASE
PT3351630T (pt) Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro
EP2646054A4 (en) METHODS OF TREATING A TUMOR USING ANTIBODY THAT IS SPECIFICALLY BOUND TO GRP94
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
IL222234A0 (en) Biomarkers for mdm2 inhibitors for use in treating disease
DK2683384T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion
HK1202127A1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy (adm) adm adm ig
EP2613151A4 (en) METHOD OF DETERMINING THE APPEARANCE OF CANCER OR THE RISK OF APPEARANCE OF CANCER
DK2542920T3 (da) Fremgangsmåde til lokal attribut sammenligning i seismisk behandling
EP2542583B8 (en) Methods for treating breast cancer
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BR112014004937A2 (pt) método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr
IL220889A (en) Anti-dll4 antibody to treat diabetes
HK1256823A1 (zh) 用α-2B腎上腺素能受體激動劑活化調節T細胞的方法
BR112014005080A2 (pt) métodos para o tratamento de câncer de mama
EP2635286A4 (en) METHOD FOR THE TREATMENT OF CANCER
PT2550296T (pt) Anticorpos monoclonais para tratamento do cancro

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.